Mitoxan (Mitoxantrone)

Mitoxantrone intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the enzyme from resealing DNA strands. This action creates double‑strand breaks, leading to apoptosis of malignant cells while sparing most normal, non‑dividing tissues.

The dose of Mitoxan is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and cardiac function, and treatment protocol. No fixed regimen is provided here; the prescriber determines the appropriate dosing schedule.

Safety data for mitoxantrone in pregnancy and lactation are limited, and the drug is generally avoided because of potential fetal toxicity and unknown effects on breast‑fed infants. Use only if the potential benefit justifies the risk, and discuss alternatives with a specialist.

To order Mitoxan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The primary alternative to mitoxantrone is the anthracycline class, such as doxorubicin. Both agents intercalate DNA, but mitoxantrone has a lower incidence of acute cardiotoxicity at equivalent doses, though cumulative cardiac risk remains. Choice depends on tumor type, prior exposure, and individual patient risk factors.

Mitoxantrone for injection must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, use validated cold‑chain containers to maintain temperature stability.

Mitoxan is supplied as a sterile solution for intravenous infusion. It is typically diluted in an appropriate carrier fluid and administered over a prescribed period, often ranging from 15 minutes to several hours, depending on the treatment protocol and patient tolerance.

The most serious adverse risks include dose‑related cardiac toxicity (which may lead to irreversible cardiomyopathy), secondary acute myeloid leukemia, and severe infections due to profound myelosuppression. Regular cardiac monitoring, blood‑count checks, and infection surveillance are essential during therapy.

Mitoxan is contraindicated in patients with pre‑existing severe cardiac disease, uncontrolled infections, known hypersensitivity to mitoxantrone or its excipients, and in pregnant or breastfeeding women unless no safer alternative exists. Caution is also advised for individuals with significant hepatic or renal impairment.